NOTE: The following includes references to in the online news media. If you are interested in seeing the full article you will need to contact archives department of the source publication. We do not have copies of any articles described on this site.

454 Life Sciences

454 Life Sciences

Study on First New Potential Drug for Tuberculosis in 40 Years ...
[excerpt] 20 /PRNewswire-FirstCall/ -- 454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation (NASDAQ:CRGN), announced today that its proprietary whole ... [/excerpt]
On Dec 20, 2004 in mysan.de

Study on First New Potential Drug for Tuberculosis in 40 Years ...
[excerpt] ...of a potential antimicrobial treatment for tuberculosis (TB) that targets a newly identified pathway discovered with the use of 454 Life Sciences' technology. ... [/excerpt]
On Dec 20, 2004 in PharmaLive.com (press release)

Study on first new potential drug for tuberculosis in 40 years
[excerpt] 454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation, announced today that its proprietary whole genome sequencing technology was used by ... [/excerpt]
On Dec 20, 2004 in News-Medical.net,